about
Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.Gene therapy for heart failure: where do we stand?Percutaneous approaches for efficient cardiac gene delivery.Drug-coated balloons in interventional cardiology.Transcatheter Left Atrial Appendage Closure Using Intracardiac Echocardiographic Guidance From the Left Atrium.EFFECTS OF PREOPERATIVE ENOXAPARIN ON BLEEDING AFTER CORONARY ARTERY BYPASS SURGERY.Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis.The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: correlation with fractional flow reserve.The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.Comparison of results of transcatheter aortic valve implantation in patients with severely stenotic bicuspid versus tricuspid or nonbicuspid valves.Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations.First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations.TAVR-Associated Prosthetic Valve Infective EndocarditisComparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcationsThe role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcationsUrinary neutrophil gelatinase-associated lipocalin as a predictor of acute kidney injury after transcatheter aortic valve implantation
P50
Q34356167-C49D783B-2A61-46B9-B73E-9FD0DA8BB501Q38073152-B48B7BA0-514C-4839-9404-7BE2638DE02DQ38113171-3F2949EA-01D7-422C-892D-DA4F512B8E76Q38153787-CA27F504-A85C-4DC9-908B-F03BDA59043CQ40645186-69D3059F-99BC-44B6-B0C7-B6CA0F40E2B5Q40944760-A62FB8E1-F7BD-4A34-8BCD-A16B6D65D363Q41486927-B5867A13-BC6B-4BC1-985F-B183DEB10A2BQ41493218-F1D45C35-3280-44DE-95FE-576BB99DF1BFQ43613852-945C7309-79D9-4963-B68C-107B76AFB89AQ46370644-D9438563-4AF9-44B1-9ABF-EE7B63674D15Q50716362-B27D0C4C-A6A3-4DAB-A3FF-917BA56850D5Q53390264-53DCA35B-6A04-4CEC-BA40-EE24B7FB2642Q54700395-ABE99DFA-F3B3-4723-BD1B-E0E0F81261FCQ57914382-F1E5E5CD-49D7-45A8-A624-3B9A219DB00DQ87008208-37117166-0DAA-4946-AD6B-AAFC78BF58CEQ95418542-7C9CD408-2EC5-455E-9C95-E2FD8F97CC23Q95523606-5D043281-39AD-4265-9B26-FBC6ACAEC7ED
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Charbel Naim
@ast
Charbel Naim
@en
Charbel Naim
@es
Charbel Naim
@nl
Charbel Naim
@sl
type
label
Charbel Naim
@ast
Charbel Naim
@en
Charbel Naim
@es
Charbel Naim
@nl
Charbel Naim
@sl
prefLabel
Charbel Naim
@ast
Charbel Naim
@en
Charbel Naim
@es
Charbel Naim
@nl
Charbel Naim
@sl
P106
P1153
55548158900
P31
P496
0000-0002-4346-3991